🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are increasing worldwide, with estimates suggesting more than 82 million infections each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Authorization

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in close succession. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This authorization represents a significant shift in the therapy of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Data and Worldwide Availability

According to data released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in numerous developing nations.

Clinicians directly involved have expressed positive views. Access to a easy-to-administer therapy like this is hailed as a "critical tool" for public health efforts. This is considered vital to reduce the burden of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.